Wednesday, February 25, 2015 11:57:50 PM
Click Here ( http://www.veracast.com/webcasts/rbc/healthcare2015/24212400739.cfm ) to listen in full CEO Renal Division Charles W. Bishop discuss Rayaldee at the 2015 RBC Capital Markets’ Healthcare Conference.
Opko CEO Renal Division Charles W. Bishop, PhD
Five products in Phase 3. Host of products in earlier stage development. Top of the list is Rayaldee, a drug that has finished Phase 3 development. We will be submitting the NDA for Rayaldee next month. Rayaldee is a treatment for Secondary Hyperparathyroidism in patients who have pre-dialysis chronic kidney disease.
This product is going to be the first with the indication of treating Secondary Hyperparathyroidism that arises from Vitamin D Insufficiency in this patient population. No other product has this indication.
We think it will be a game changer for our pre-dialysis patients.
Rayaldee achieves Vitamin D sufficiency much more readily than any other product that is available. It lowers PTH as well as any product that is in the market. It does two things that Physician's want to do. Rayaldee allows Physician's to use one drug to get those two things done more effectively and safely.
Market for Rayaldee is large. Millions of patients that we target with Stage 3 & 4 CKD, one quarter are treated with active Vitamin D Hormones and one third are treated with Nutritional Vitamin D. Because neither of these options are very good about one half of the patient's are not treated at all. We believe Rayaldee can take share from all three of these categories and in fact expand the market.
With Rayaldee's target pricing at about $10,000 per year, you can see with every million patient's we have under treatment we will have a major financial opportunity.
"Rayaldee will be the only product in history with this indication." Charles W. Bishop, PhD
Recent OPK News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/20/2024 06:56:10 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 09/18/2024 08:13:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 09:00:42 PM
- Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health • PR Newswire (US) • 09/16/2024 11:30:00 AM
- Form DEFR14A - Revised definitive proxy soliciting materials • Edgar (US Regulatory) • 08/30/2024 09:01:33 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/23/2024 09:33:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2024 09:23:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:50:25 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/12/2024 10:27:05 PM
- Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 08/09/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 09:39:52 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 08:12:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 08:07:42 PM
- OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results • GlobeNewswire Inc. • 08/07/2024 08:06:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 08:21:51 PM
- OPKO Health to Report Second Quarter 2024 Financial Results on August 7, 2024 • GlobeNewswire Inc. • 08/01/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/31/2024 09:03:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 11:49:22 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 07/26/2024 11:43:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 11:18:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 11:15:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 11:11:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 11:08:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 11:05:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/23/2024 09:16:09 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM